Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - influwenza, bniedem - vaċċini kontra l-influwenza, influwenza, ħaj attenwat - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. l-użu ta 'fluenz tetra għandu jkun ibbażat fuq rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propanediol monohydrate - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogi użati fid-dijabete - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. barra minn hekk għall-prodotti mediċinali oħra għat-trattament tad-dijabete tat-tip 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 u 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - gefitinib - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - iressa huwa indikat għall-kura ta 'pazjenti adulti b'lokalment avvanzat jew dak metastatiku li mhux żgħar tal-pulmun taċ-ċelluli tal-kanċer b'mutazzjonijiet li jattivaw tal-epidermali-tkabbir tal-fattur-riċetturi ta' tyrosine kinase.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

inceptua ab - ocriplasmin - mard tar-retina - oftalmoloġiċi - jetrea huwa indikat fl-adulti għat-trattament ta 'traction vitreomacular (vmt), inkluż meta assoċjat ma' toqba makulari ta 'dijametru ta' 400 mikron jew anqas.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - palifermin - mukosite - il-prodotti terapewtiċi l-oħra kollha - kepivance huwa indikat li tnaqqas l-inċidenza, it-tul u s-severità tal-mucositis orali fil-pazjenti adulti ma malignancies ħematoloġiċi li jirċievu radiochemotherapy ta ' myeloablative assoċjati ma ' l-inċidenza għolja ta ' mucositis ħorox u li jeħtieġu haematopoietic-zokk-ċelloli awtoloġiċi appoġġ.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab  - metformin hydrochloride, saxagliptin hydrochloride - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - komboglyze huwa indikat kif frozen tad-dieta u jeżerċitaw biex jitjieb il-kontroll ta ' glycaemic fil-pazjenti adulti età 18-il sena u aktar antiki ma tip-2 diabetes mellitus jirriżultax kkontrollata tagħhom bħala tollerat tad-doża ta ' metformin waħdu jew dawk diġà qed ittrattati bil-kombinazzjoni ta ' saxagliptin u metformin bħala pilloli separati. komboglyze huwa indikat ukoll f'kumbinazzjoni ma ' l-insulina (i. terapija ta ' kumbinazzjoni tripla) bħala żieda mad-dieta u l-eżerċizzju biex itejjeb il-kontroll gliċemiku f'pazjenti adulti minn 18-il sena u akbar b'dijabete tat-tip 2 mellitus meta l-insulina u metformin waħdu ma jipprovdux kontroll gliċemiku adegwat.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - libertek huwa indikat għall-manutenzjoni trattament severi kronika eliminat pulmonari marda (copd) (fev1 bronchodilator wara inqas minn 50% mbassra) assoċjati ma ' bronchitis kroniċi fil-pazjenti adulti bi storja ta ' spiss exacerbations bħala żieda trattament bronchodilator.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astra zeneca ab - saxagliptin, dapagliflozin propanedjol monohydrate - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - drogi użati fid-dijabete - qtern, taħlita fissa tad-doża ta saxagliptin u dapagliflozin, huwa indikat f'adulti ta ' 18-il sena u akbar b'dijabete mellitus tip 2:biex ittejjeb il-kontroll gliċemiku meta metformin u/jew mediċina tat-tip sulphonylurea (su) u waħda mill-monokomponenti tal-qtern ma jipprovdux kontroll gliċemiku adegwat,meta diġà qegħdin jiġu ttrattati bil-kombinazzjoni ħielsa ta dapagliflozin u saxagliptin. (ara sezzjonijiet 4. 2, 4. 4, 4. 5 u 5. 1 għall-dejta disponibbli dwar il-kombinazzjonijiet studjat.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - palivizumab - infezzjonijiet ta 'virus sintetiku respiratorju - sera immuni u immunoglobulini, - synagis huwa indikat għall-prevenzjoni ta serji aktar baxx respiratorju-passaġġ-marda li jeħtieġu kura fl-isptar kkawżat mill-virus sinktjali respiratorju (rsv), fi tfal b'riskju għoli għall-marda rsv:it-tfal li twieldu wara 35 ġimgħa ta 'ġestazzjoni jew inqas u inqas minn età ta' sitt xhur fil-bidu tal-istaġun ta 'rsv;tfal ta' inqas minn sentejn u li jeħtieġu trattament għad-displasja bronkopulmonari fl-aħħar sitt xhur;tfal ta ' inqas minn sentejn u bil-ħruġ emodinamikament sinifikanti ta mard tal-qalb konġenitali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi oħra, inibituri tal-proteina kinase - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.